Literature DB >> 1277729

Influence of acute viral hepatitis on disposition and pharmacologic effect of warfarin.

R L Williams, W L Schary, T F Blaschke, P J Meffin, K L Melmon, M Rowland.   

Abstract

Five patients received a small oral dose of warfarin during and after recovery from acute viral hepatitis. Mean (+/- SD) clearance, volume of distribution, and half-life of the drug were 6.1 +/- 0.9 ml/hr/kg, 0.09 +/- 0.04 L/kg, and 23 +/- 5 hr, respectively, during the acute period. After apparent recovery, observed values were 6.1 +/- 0.7 ml/hr/kg, 0.21 +/- 0.02 L/kg, and 25 +/- 3 hr. These differences were not significant. Pattern of renal elimination of warfarin metabolites and drug protein binding did not change between the two phases. During the acute period of illness, prothrombin time increased in 2 of the 5 subjects, but remained within normal limits in all participants during the recovery period. This study shows that warfarin disposition may not change as a consequence of mild or moderate hepatic impairment.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1277729     DOI: 10.1002/cpt197620190

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  10 in total

Review 1.  Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment.

Authors:  Gail D Anderson; Shahin Hakimian
Journal:  Clin Pharmacokinet       Date:  2014-01       Impact factor: 6.447

Review 2.  Guide to drug dosage in hepatic disease.

Authors:  N M Bass; R L Williams
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

Review 3.  Protein binding of coumarin anticoagulants in disease states.

Authors:  K Bachmann; R Shapiro
Journal:  Clin Pharmacokinet       Date:  1977 Mar-Apr       Impact factor: 6.447

4.  An evaluation of urinary D-glucaric acid excretion during acute hepatitis in man.

Authors:  M Carrella; A D'Arienzo; G Manzillo; F De Ritis
Journal:  Am J Dig Dis       Date:  1978-01

Review 5.  Protein binding and kinetics of drugs in liver diseases.

Authors:  T F Blaschke
Journal:  Clin Pharmacokinet       Date:  1977 Jan-Feb       Impact factor: 6.447

6.  Risk factors of drug interaction between warfarin and nonsteroidal anti-inflammatory drugs in practical setting.

Authors:  Kyung Hee Choi; Ah Jeong Kim; In Ja Son; Kyung-Hwan Kim; Ki-Bong Kim; Hyuk Ahn; Eun Bong Lee
Journal:  J Korean Med Sci       Date:  2010-02-17       Impact factor: 2.153

7.  Reduction of paracetamol and aspirin metabolism during viral hepatitis.

Authors:  C Jorup-Rönström; B Beermann; E Wåhlin-Boll; A Melander; S Britton
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

8.  Disposition, Elimination and Haemodynamic Effects of Gallopamil in Patients with Fatty Liver Disease.

Authors:  M Siepmann; B R Rao; W Kirch
Journal:  Clin Drug Investig       Date:  1995-12       Impact factor: 2.859

Review 9.  Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy.

Authors:  H G Shetty; A G Fennerty; P A Routledge
Journal:  Clin Pharmacokinet       Date:  1989-04       Impact factor: 6.447

10.  Genetic and environmental factors affecting host response to drugs and other chemical compounds in our environment.

Authors:  E S Vesell; G T Passananti
Journal:  Environ Health Perspect       Date:  1977-10       Impact factor: 9.031

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.